140
Participants
Start Date
April 30, 2011
Primary Completion Date
August 31, 2012
Study Completion Date
January 31, 2013
Eniluracil
Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, \& 15
5-Fluorouracil
5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, \& 16
Leucovorin
Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, \& 17
Capecitabine
Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
RECRUITING
The Methodist Hospital Cancer Center, Houston
RECRUITING
Banner MD Anderson Cancer Center, Gilbert
RECRUITING
Arkhangelsk Regional Clinical Oncology Center, Arkhangelsk
RECRUITING
Oncology Center No. 2 Krasnodar Regional Healthcare Dept, Sochi
RECRUITING
Chelyabinsk Regional Clinical Oncology, Chelyabinsk
RECRUITING
Clinical Oncology Center #1, Krasnodar
RECRUITING
Moscow Hertzen Oncology Research Institute, Moscow
RECRUITING
Russian Oncological Research Center n.s. Blokhin, Moscow
RECRUITING
Orenburg Regional Clinical Oncology Center, Orenburg
RECRUITING
Pyatigorsk Oncology Center, Pyatigorsk
RECRUITING
Republic Oncology Center, Republic of Karelia
RECRUITING
City Clinical Oncology Center, Saint Petersburg
RECRUITING
Laboratory of Thoracic Oncology of Research Institute of Pulmonary at St. Petersburg State Medical University n.a. I.P. Pavlov, Saint Petersburg
RECRUITING
Leningrad Regional Oncology Center, Saint Petersburg
RECRUITING
Road Clinical Hospital of the Russian Railways, Saint Petersburg
RECRUITING
Stavropol Regional Clinical Oncology Center, Stavropol
Lead Sponsor
Adherex Technologies, Inc.
INDUSTRY